Condition: Langerhans Cell Histiocytosis (LCH) · Juvenile Xanthogranuloma (JXG) · Rosai-Dorfman Disease (RDD) · Sponsor: Children's Hospital Medical Center, Cincinnati
The purpose of this study is to see if treatment with mirdametinib in patients with Langerhans cell histiocytosis (LCH) or other histiocytic disorders will be better than current treatments and with fewer side effects.
This description comes directly from the study's public registry record.
Monica Trapp · (513) 803-8574 · monica.trapp@cchmc.org
Caitlin Cottrell · (513) 803-7039 · Caitlin.Cottrell@cchmc.org
Always discuss trial participation with your own doctor first.
| Cincinnati Children's Hospital Medical Center | Cincinnati, Ohio, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06153173